scholarly journals P6508Balance of risk and benefit of spironolactone according to renal function in heart failure patients with preserved ejection fraction

2018 ◽  
Vol 39 (suppl_1) ◽  
Author(s):  
I E Beldhuis ◽  
P L Myhre ◽  
B Claggett ◽  
K Damman ◽  
J C Fang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Function ◽  
Ejection Fraction ◽  
Preserved Ejection Fraction ◽  
Heart Failure Patients ◽  
Risk And Benefit

Comparison of risk factors for acute worsening renal function in heart failure patients with and without preserved ejection fraction

2015 ◽  
Vol 26 (8) ◽  
pp. 599-602 ◽  
Author(s):  
Tamiharu Yamagishi ◽  
Kenichi Matsushita ◽  
Toshinori Minamishima ◽  
Ayumi Goda ◽  
Konomi Sakata ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Renal Function ◽  
Ejection Fraction ◽  
Preserved Ejection Fraction ◽  
Heart Failure Patients ◽  
Worsening Renal Function

Galectin-3 in Heart Failure – Linking Fibrosis, Remodelling and Progression

2010 ◽  
Vol 6 (2) ◽  
pp. 33 ◽  
Author(s):  
Christopher R deFilippi ◽  
G Michael Felker ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Risk Stratification ◽  
Cardiac Fibrosis ◽  
The Elderly ◽  
Preserved Ejection Fraction ◽  
Heart Failure Patients ◽  
Large Populations ◽  
Galectin 3

For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodelling that represents an intriguing link between inflammation and fibrosis. In this article we review the biology of galectin-3, recent clinical research and its application in the management of heart failure patients.

Sign in / Sign up

Export Citation Format

Share Document